These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

9739 related items for PubMed ID: 10803710

  • 1. Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.
    del Olmo M, Alonso-Varona A, Castro B, Calle Y, Bilbao P, Palomares T.
    Melanoma Res; 2000 Apr; 10(2):103-12. PubMed ID: 10803710
    [Abstract] [Full Text] [Related]

  • 2. L-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases.
    Bilbao P, del Olmo M, Alonso-Varona A, Castro B, Bilbao J, Palomares T.
    Melanoma Res; 2002 Feb; 12(1):17-26. PubMed ID: 11828254
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells.
    Palomares T, Alonso-Varona A, Alvarez A, Castro B, Calle Y, Bilbao P.
    Clin Exp Metastasis; 1997 May; 15(3):329-37. PubMed ID: 9174132
    [Abstract] [Full Text] [Related]

  • 4. Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat.
    Rose DM, Hochwald SN, Harrison LE, Burt M.
    J Surg Res; 1996 May; 62(2):224-8. PubMed ID: 8632643
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
    Palomares T, Bilbao P, del Olmo M, Castro B, Calle Y, Alonso-Varona A.
    Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
    [Abstract] [Full Text] [Related]

  • 6. Cytomodulation of interleukin-2 effect by L-2-oxothiazolidine-4-carboxylate on human malignant melanoma.
    del Olmo M, Alonso-Varona A, Castro B, Bilbao P, Palomares T.
    Cancer Immunol Immunother; 2006 Aug; 55(8):948-57. PubMed ID: 16220324
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteine prodrug, and cysteine.
    Gwilt PR, Radick LE, Li XY, Whalen JJ, Leaf CD.
    J Clin Pharmacol; 1998 Oct; 38(10):945-50. PubMed ID: 9807976
    [Abstract] [Full Text] [Related]

  • 8. Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells.
    Chen X, Batist G.
    Biochem Pharmacol; 1998 Sep 15; 56(6):743-9. PubMed ID: 9751079
    [Abstract] [Full Text] [Related]

  • 9. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model.
    Baruchel S, Wang T, Farah R, Jamali M, Batist G.
    Biochem Pharmacol; 1995 Oct 26; 50(9):1505-8. PubMed ID: 7503802
    [Abstract] [Full Text] [Related]

  • 10. Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response.
    Wang T, Chen X, Schecter RL, Baruchel S, Alaoui-Jamali M, Melnychuk D, Batist G.
    J Pharmacol Exp Ther; 1996 Mar 26; 276(3):1169-73. PubMed ID: 8786549
    [Abstract] [Full Text] [Related]

  • 11. Comparison of N-acetylcysteine and l-2-oxothiazolidine-4-carboxylate as cysteine deliverers and glutathione precursors in human malignant melanoma transplants in mice.
    Dizdar N, Kullman A, Kågedal B.
    Cancer Chemother Pharmacol; 2000 Mar 26; 45(3):192-8. PubMed ID: 10663636
    [Abstract] [Full Text] [Related]

  • 12. Protective effects of L-2-oxothiazolidine-4-carboxylate treatment on cyclophosphamide-induced cystitis in rats.
    Safron J, Rice D, Gordon D, Leaf C, White R.
    J Urol; 1997 May 26; 157(5):1946-50. PubMed ID: 9112569
    [Abstract] [Full Text] [Related]

  • 13. Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
    Terrill JR, Boyatzis A, Grounds MD, Arthur PG.
    Int J Biochem Cell Biol; 2013 Sep 26; 45(9):2097-108. PubMed ID: 23892094
    [Abstract] [Full Text] [Related]

  • 14. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.
    Roberts JC, Francetic DJ, Zera RT.
    Cancer Chemother Pharmacol; 1991 Sep 26; 28(3):166-70. PubMed ID: 1855273
    [Abstract] [Full Text] [Related]

  • 15. Treatment with glutathione precursor decreases cytokine activity.
    Pena LR, Hill DB, McClain CJ.
    JPEN J Parenter Enteral Nutr; 1999 Sep 26; 23(1):1-6. PubMed ID: 9888410
    [Abstract] [Full Text] [Related]

  • 16. L-2-Oxothiazolidine-4-carboxylic acid prevents endotoxin-induced cardiac dysfunction.
    Poon BY, Goddard CM, Leaf CD, Russell JA, Walley KR.
    Am J Respir Crit Care Med; 1998 Oct 26; 158(4):1109-13. PubMed ID: 9769268
    [Abstract] [Full Text] [Related]

  • 17. Effects of cysteine pro-drugs on acetaminophen-induced hepatotoxicity.
    Hazelton GA, Hjelle JJ, Klaassen CD.
    J Pharmacol Exp Ther; 1986 Apr 26; 237(1):341-9. PubMed ID: 3958971
    [Abstract] [Full Text] [Related]

  • 18. Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug (Procysteine).
    Moberly JB, Logan J, Borum PR, Story KO, Webb LE, Jassal SV, Mupas L, Rodela H, Alghamdi GA, Moran JE, Wolfson M, Martis L, Oreopoulos DG.
    J Am Soc Nephrol; 1998 Jun 26; 9(6):1093-9. PubMed ID: 9621294
    [Abstract] [Full Text] [Related]

  • 19. Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice.
    Conklin DJ, Haberzettl P, Jagatheesan G, Baba S, Merchant ML, Prough RA, Williams JD, Prabhu SD, Bhatnagar A.
    Toxicol Appl Pharmacol; 2015 Jun 01; 285(2):136-48. PubMed ID: 25868843
    [Abstract] [Full Text] [Related]

  • 20. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.
    Russo A, DeGraff W, Friedman N, Mitchell JB.
    Cancer Res; 1986 Jun 01; 46(6):2845-8. PubMed ID: 2421885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 487.